PDCD1 and neoplasm: In keeping with these findings, the EOAI3402143 treatment alone or combination with anti-CTLA-4 significantly reduced the PD-1 protein abundance in tumor-infiltrating CD3+ T cells and enhanced the production of IFN-γ, TNF, and GzmB in tumor-infiltrating CD8+ T cells compared with control treatment (Fig. 6n–q, and Supplementary Fig. 10l).